Clonal blood mutations are common in older people with HIV and track with mortality and cancer
In about 1,600 older Swiss adults with HIV, 25% carried CHIP mutations and 16% had chromosomal alterations. CHIP linked to higher mortality and myeloid cancer risk.
Summary
Clonal hematopoiesis (CH) is the expansion of blood stem cell clones carrying somatic mutations (CHIP) or large chromosomal alterations (mCAs). It rises with age and marks inflammatory and disease risk. In the Swiss HIV Cohort Study, 25% of 1,629 older adults had CHIP and 16% of 1,782 had mCAs. CHIP was associated with higher all-cause mortality (HR 1.3) and myeloid cancer (HR 9.4). CH also tracked with a lower CD4:CD8 ratio, higher viral load, late ART start and exposure to older toxic ART drugs. This is observational, so it shows association, not cause. Findings suggest CH and chronic immune activation may reinforce each other in people with HIV.
Detailed Summary
People with HIV often show earlier age-related disease, and non-AIDS cancers and cardiovascular disease are now leading causes of death. Clonal hematopoiesis (CH) may help explain this. In CHIP, blood stem cells with leukemia-associated mutations (such as DNMT3A, TET2 and ASXL1) expand and push innate immune cells toward more inflammation. This inflammation may in turn favor further clonal expansion. mCAs are large chromosomal gains, losses or copy-neutral losses, including loss of the Y or X chromosome.
Researchers analyzed participants in the Swiss HIV Cohort Study, a prospective cohort. CHIP was assessed by deep (>500x) targeted sequencing of 24 genes in 1,629 people aged about 60 or older, using a VAF threshold of 2%. mCAs were called from genotyping arrays in 1,782 people. Associations with clinical variables, blood counts, mortality and disease were tested with regression and Cox models. Nominal P values were reported.
CHIP was found in 25% of participants, mostly in DNMT3A (44%), TET2 (29%) and ASXL1 (9%). Raising the VAF threshold to 5% and 10% cut carriers to 10% and 3.7%. mCAs were found in 16%: autosomal in 6%, Y loss in 10% of men and X loss in 13% of women. CHIP and autosomal mCAs co-occurred more than expected (OR 1.7, P=.02). Age was the strongest correlate. Among HIV factors, injection drug use and exposure to older toxic ART drugs (zidovudine, stavudine, didanosine, zalcitabine) were most associated with CH. Higher viral load, longer untreated infection and a lower CD4:CD8 ratio, driven by higher CD8 counts, also tracked with CH.
CHIP was associated with all-cause mortality (HR 1.3, P=.02) and myeloid cancer (HR 9.4, P=.01). Co-occurring CHIP and mCAs showed HR >20 for lymphoid cancer. Other associations included cardiovascular disease, diabetes and lower eGFR. Higher-VAF CHIP was associated with liver fibrosis, osteoporosis, neurocognitive impairment and multimorbidity. Smoking was not associated with CH. Associations with chronic kidney disease and osteoporosis seen in the general population were not clearly replicated overall.
The authors propose a feedback loop in which HIV-driven immune activation promotes CH and CH sustains inflammation. The design cannot prove this. It is observational, uses nominal P values across many tests, and some effect estimates (such as the HR >20) rest on few events. The inflammatory link rests on proxy blood markers, not direct inflammatory measures. The study had no HIV-negative control group, so the claim that CHIP is elevated in PWH rests on earlier work. Interventions that lower CH or its risks have not been tested here.
Key Findings
- CHIP was present in 25% of 1,629 older PWH; mCAs in 16% of 1,782, with 6% autosomal.
- CHIP was associated with all-cause mortality (HR 1.3) and myeloid cancer (HR 9.4); these are associations, not proven causal effects.
- Co-occurring CHIP and mCAs showed HR >20 for lymphoid cancer, an estimate likely based on few events.
- CH tracked with lower CD4:CD8 ratio, higher CD8 counts, higher viral load, late ART and older toxic ART drugs.
- Smoking was not associated with CH, and links to kidney disease and osteoporosis were not clearly replicated.
Methodology
Observational analysis within the prospective Swiss HIV Cohort Study. CHIP was detected by >500x targeted sequencing of 24 genes (VAF ≥2%, n=1,629); mCAs by genotyping arrays with the MoChA pipeline (n=1,782). Associations were tested with logistic, Poisson, mixed linear and Cox models, with nominal P values and no multiple-testing correction.
Study Limitations
Observational design means no causal inference, and the feedback-loop mechanism is hypothesized, not tested. There was no HIV-negative comparison group, nominal P values were used across many tests, and some outcomes had few events and wide uncertainty. Participants were mostly older and of European ancestry, and inflammation was inferred from proxies such as CD4:CD8 and viral load.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe:
